Form 8-K

8-K — ANGIODYNAMICS INC

Accession: 0001140361-26-012891

Filed: 2026-04-02

Period: 2026-04-02

CIK: 0001275187

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20069681_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20069681_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (ef20069681_ex99-2.htm)

GRAPHIC (ef20069681_ex99-2slide1.jpg)

GRAPHIC (ef20069681_ex99-2slide2.jpg)

GRAPHIC (ef20069681_ex99-2slide3.jpg)

GRAPHIC (ef20069681_ex99-2slide4.jpg)

GRAPHIC (ef20069681_ex99-2slide5.jpg)

GRAPHIC (ef20069681_ex99-2slide6.jpg)

GRAPHIC (ef20069681_ex99-2slide7.jpg)

GRAPHIC (ef20069681_ex99-2slide8.jpg)

GRAPHIC (ef20069681_ex99-2slide9.jpg)

GRAPHIC (ef20069681_ex99-2slide10.jpg)

GRAPHIC (ef20069681_ex99-2slide11.jpg)

GRAPHIC (ef20069681_ex99-2slide12.jpg)

GRAPHIC (ef20069681_ex99-2slide13.jpg)

GRAPHIC (ef20069681_ex99-2slide14.jpg)

GRAPHIC (ef20069681_ex99-2slide15.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20069681_8k.htm · Sequence: 1

false000127518700012751872026-04-022026-04-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2026

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-50761

11-3146460

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

14 Plaza Drive, Latham, New York

12110

(Address of Principal Executive Offices)

(Zip Code)

(518) 795-1400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share

ANGO

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or

Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 – Results of Operations and Financial Condition.

On April 2, 2026, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal third quarter

ended February 28, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of

the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities

Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 – Regulation FD Disclosure.

Presentation slides discussing AngioDynamics and its fiscal third quarter ended February 28, 2026 are furnished herewith as Exhibit 99.2.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for

purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange

Act.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and

objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects”, “optimistic,” or variations of such words

and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially

from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its

existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to

effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical

trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party

distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the

effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of

AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form

10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Description

99.1

Press Release, dated April 2, 2026.

99.2

Presentation, dated April 2, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.

(Registrant)

Date: April 2, 2026

By:

/s/ Lawrence T. Weiss

Name:

Lawrence T. Weiss

Title:

Senior Vice President, Chief Legal Officer and Corporate Secretary

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20069681_ex99-1.htm · Sequence: 2

Exhibit 99.1

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued

Profitability

•

Med Tech segment delivered its sixth consecutive quarter of double-digit growth

•

Strong adjusted EBITDA

•

Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA

LATHAM, N.Y.--(BUSINESS WIRE)— April 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy

blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026.

Fiscal Year 2026 Third Quarter Highlights

Quarter Ended

February 28, 2026

Pro Forma* YoY Growth

Net Sales

$78.4 million

8.9%

Med Tech Net Sales

$37.3 million

19.0%

Med Device Net Sales

$41.1 million

1.1%

•

GAAP gross margin of 52.9%

•

GAAP loss per share of $0.19

•

Adjusted loss per share of $0.07

•

Adjusted EBITDA of $1.8 million

•

Ended fiscal 2026 third quarter with $37.8 million in cash, in line with expectations

*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC, Midline and tip location product portfolios

divested in February 2024, as well as the discontinued Radiofrequency and Syntrax support catheter products in February 2024.

"We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth," commented Jim

Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we

have the strongest mechanical thrombectomy portfolio available. Auryon remains a consistent growth driver, and NanoKnife is accelerating adoption as we see our commercial strategy supported by the recently effective CPT 1 code for prostate. Beyond

the demonstrated topline growth in our higher margin Med Tech businesses, the disciplined execution of our operating initiatives translated into another quarter of strong positive adjusted EBITDA."

Mr. Clemmer continued, "Our year-to-date performance gives us confidence in our ability to continue to deliver on our strategy and vision. The progress we have made over

the past several years is showing up in our results, and we remain focused on driving sustained, profitable growth as we head into the fourth quarter and fiscal 2027."

Fiscal Year 2026 Third Quarter Financial Results

Unless otherwise noted, all financial comparisons below are presented on a pro forma basis excluding the Dialysis and BioSentry businesses divested in June 2023, the

PICC, Midline, and tip location product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.

Net sales for the third quarter of fiscal year 2026 were $78.4 million, an increase of 8.9% compared to the prior-year quarter.

Med Tech net sales were $37.3 million, a 19.0% increase from $31.3 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, our

thrombus management platform which is led by AlphaVac and AngioVac, and the NanoKnife irreversible electroporation platform.

Growth during the quarter was driven by solid performance across the Med Tech segment. Auryon sales were $16.3 million, an increase of 17.9% compared to the prior-year

quarter, our Mechanical Thrombectomy business, which includes AngioVac and AlphaVac, delivered sales of $11.5 million, an increase of 17.9% compared to the prior-year quarter, and NanoKnife sales were $7.6 million, an increase of 21.0% compared to

the prior-year quarter, including 20.0% growth in probes and 24.9% growth in capital sales.

Med Device net sales were $41.1 million, a 1.1% increase compared to $40.7 million in the prior-year period.

Gross margin for the third quarter of fiscal 2026 was 52.9%, which was 110 basis points lower compared to the third quarter of fiscal 2025, primarily driven by the impact and timing of tariffs, increased inflation and certain costs associated with the Company’s manufacturing transition, all of which were in-line with the Company’s

expectations.

The Company recorded a GAAP net loss of $8.1 million, or a loss per share of $0.19, in the third quarter of fiscal 2026. Excluding the items shown in the

non-GAAP reconciliation table below, adjusted net loss for the third quarter of fiscal 2026 was $3.0 million, or a loss per share of $0.07. This compares to an adjusted net loss during the fiscal third quarter of 2025 of $3.1 million, or a loss per share of $0.08.

Adjusted EBITDA in the third quarter of fiscal 2026, excluding the items shown in the

non-GAAP reconciliation table below, was $1.8 million, compared to $1.3 million in the third quarter of fiscal 2025.

Tariff related expenses were $1.3 million during the quarter, compared to zero for the prior year quarter, in-line with the Company’s expectations.

In the third quarter of fiscal 2026, the Company used $3.0 million of cash, slightly less than the Company’s expectations.

At February 28, 2026, the Company had $37.8 million in cash and maintains a debt-free balance sheet.

Fiscal Year 2026 Financial Guidance

For fiscal year 2026 the Company now expects:

Guidance Metric

Guidance Action

Current Guidance

(as of April 2, 2026)

Previous Guidance

(as of January 6, 2026)

Net Sales

Increased

$313.5 - $315.5 M

$312 - $314 M

Med Tech Net Sales Growth

Increased

15% - 17%

14% - 16%

Med Device Net Sales Growth

Increased

Approx. 1%

0% - 1%

Gross Margin

Unchanged

53.5% - 55.5%

Adjusted EBITDA

Increased

$10.0 - $12.0 M

$8.0 - $10.0 M

Adjusted EPS

Increased

($0.30) – ($0.23)

($0.33) – ($0.23)

Cash Flow Guidance

The Company remains on course to illustrate that its business model will be cash flow positive and expects to generate substantial cash in the fourth fiscal

quarter, in line with historical trends. During the third fiscal quarter, the Company was advised by its sterilization vendors of their plan to implement two upcoming temporary shutdowns to perform maintenance activities during the fourth quarter. To

proactively address this and avoid any potential commercial disruptions, the Company plans to increase inventory levels for certain products during the fourth quarter. The net result will be the acceleration of the use of approximately $3.0 to $5.0

million of cash to build inventory in the back half of fiscal year 2026, which normally would have been used in future periods. This may result in cash flow for fiscal year 2026 being slightly negative. The Company noted that there is no modification

to the positive cash generation pathway that it has been on or the cash generation profile of the business.

Tariff Related Guidance Assumptions

For the full fiscal year 2026, the Company continues to expect a $4.0 - $6.0 million impact from tariffs, which are included in the above provided

guidance.

All assumptions made related to expected tariff impacts are based on the Company’s point of view on the current tariff situation, as of April 2, 2026. As

the situation is fluid, these assumptions may change in the future.

Conference Call

The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial

1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be

available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Thursday, April 9, 2026 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or

+1-412-317-6671 (international) and enter the passcode 13758776.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying

trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release,

AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these

measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics'

underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur

from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding

cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in

fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding

AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for

future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are

forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics'

expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new

products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively

compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials,

overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or

joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic,

credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain

regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year

ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Investors:

Stephen Trowbridge

Executive Vice President & CFO

518-795-1408

strowbridge@angiodynamics.com

Media:

Saleem Cheeks

Vice President, Communications

518-795-1174

scheeks@angiodynamics.com

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

Three Months Ended

Actual (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net sales

78,423

)

78,421

72,004

72,013

Cost of sales (exclusive of intangible amortization)

36,944

—

36,944

33,147

33,153

Gross margin

41,479

)

41,477

38,857

38,860

% of net sales

52.9

54.0

Operating expenses

Research and development

7,084

—

7,084

6,913

—

6,913

Sales and marketing

27,437

—

27,437

25,504

—

25,504

General and administrative

10,719

—

10,719

10,490

—

10,490

Amortization of intangibles

2,668

—

2,668

2,598

—

2,598

Change in fair value of contingent consideration

—

Acquisition, restructuring and other items, net

6,522

—

6,522

3,286

)

3,283

Total operating expenses

54,430

—

54,430

48,831

)

48,828

Operating loss

(12,951

)

(12,953

)

(9,974

)

(9,968

)

Interest income (expense), net

(88

)

—

(88

)

135

—

135

Other income (expense), net

4,967

(5,000

)

(33

)

5,430

(5,500

)

(70

)

Total other income (expense), net

4,879

(5,000

)

(121

)

5,565

(5,500

)

Loss before income tax (benefit) expense

(8,072

)

(5,002

)

(13,074

)

(4,409

)

(5,494

)

(9,903

)

Income tax (benefit) expense

—

)

—

)

Net loss

(8,084

)

(5,002

)

(13,086

)

(4,407

)

(5,494

)

(9,901

)

Loss per share

Basic

(0.19

)

(0.31

)

(0.11

)

(0.24

)

Diluted

(0.19

)

(0.31

)

(0.11

)

(0.24

)

Weighted average shares outstanding

Basic

41,596

40,853

Diluted

41,596

40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and

February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

Nine Months Ended

Actual (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net sales

233,567

)

233,565

212,340

188

212,528

Cost of sales (exclusive of intangible amortization)

105,448

—

105,448

96,853

155

97,008

Gross margin

128,119

)

128,117

115,487

115,520

% of net sales

54.9

54.4

Operating expenses

Research and development

21,269

—

21,269

19,632

—

19,632

Sales and marketing

82,278

—

82,278

76,698

—

76,698

General and administrative

33,425

—

33,425

31,856

—

31,856

Amortization of intangibles

7,964

—

7,964

7,730

—

7,730

Change in fair value of contingent consideration

—

272

—

272

Acquisition, restructuring and other items, net

12,915

—

12,915

13,465

161

13,626

Total operating expenses

157,851

—

157,851

149,653

161

149,814

Operating loss

(29,732

)

(29,734

)

(34,166

)

(128

)

(34,294

)

Interest income (expense), net

(194

)

—

(194

)

975

—

975

Other income (expense), net

4,661

(5,000

)

(339

)

5,269

(5,500

)

(231

)

Total other income (expense), net

4,467

(5,000

)

(533

)

6,244

(5,500

)

744

Loss before income tax expense

(25,265

)

(5,002

)

(30,267

)

(27,922

)

(5,628

)

(33,550

)

Income tax expense

—

Net loss

(25,337

)

(5,002

)

(30,339

)

(27,943

)

(5,628

)

(33,571

)

Loss per share

Basic

(0.61

)

(0.73

)

(0.68

)

(0.82

)

Diluted

(0.61

)

(0.73

)

(0.68

)

(0.82

)

Weighted average shares outstanding

Basic

41,467

40,809

Diluted

41,467

40,809

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

February 28, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss) and Pro Forma Adjusted Net Loss:

Three Months Ended

Actual(1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net loss

(8,084

)

(5,002

)

(13,086

)

(4,407

)

(5,494

)

(9,901

)

Amortization of intangibles

2,668

—

2,668

2,598

—

2,598

Change in fair value of contingent consideration

—

Acquisition, restructuring and other items, net (3)

6,522

—

6,522

3,286

)

3,283

Tax effect of non-GAAP items (4)

(245

)

1,150

905

(350

)

1,264

914

Adjusted net income (loss)

861

(3,852

)

(2,991

)

1,167

(4,233

)

(3,066

)

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted and Pro Forma Adjusted Diluted Income (Loss) Per Share:

Three Months Ended

Actual(1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Diluted loss per share

(0.19

)

(0.12

)

(0.31

)

(0.11

)

(0.13

)

(0.24

)

Amortization of intangibles

0.06

—

0.06

—

0.06

Change in fair value of contingent consideration

—

0.01

—

0.01

Acquisition, restructuring and other items, net (3)

0.16

—

0.16

0.08

(0.01

)

0.07

Tax effect of non-GAAP items (4)

(0.01

)

0.03

0.02

(0.01

)

0.03

0.02

Adjusted diluted income (loss) per share

0.02

(0.09

)

(0.07

)

0.03

(0.11

)

(0.08

)

Adjusted diluted sharecount (5)

43,752

41,596

42,091

40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

2025, respectively .

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain

litigation, and other items.

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax

assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.

(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands)

Reconciliation of Net Loss and non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA:

Three Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net loss

(8,084

)

(5,002

)

(13,086

)

(4,407

)

(5,494

)

(9,901

)

Income tax expense

—

)

—

)

Interest expense (income), net

—

(135

)

—

(135

)

Depreciation and amortization

5,591

—

5,591

6,319

—

6,319

Change in fair value of contingent consideration

—

Stock based compensation

2,684

—

2,684

2,398

—

2,398

Acquisition, restructuring and other items, net (3)

6,522

—

6,522

2,623

)

2,620

Adjusted EBITDA

6,813

(5,002

)

1,811

6,836

(5,497

)

1,339

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

2025, respectively .

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain

litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

Reconciliation of Net Loss to non-GAAP Adjusted Net Loss and Pro Forma Adjusted Net Loss:

Nine Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net loss

(25,337

)

(5,002

)

(30,339

)

(27,943

)

(5,628

)

(33,571

)

Amortization of intangibles

7,964

—

7,964

7,730

—

7,730

Change in fair value of contingent consideration

—

272

—

272

Acquisition, restructuring and other items, net (3)

12,915

—

12,915

13,465

161

13,626

Tax effect of non-GAAP items (4)

1,081

1,150

2,231

1,506

1,257

2,763

Adjusted net loss

(3,377

)

(3,852

)

(7,229

)

(4,970

)

(4,210

)

(9,180

)

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted and Pro Forma Adjusted Diluted Loss Per Share:

Nine Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Diluted loss per share

(0.61

)

(0.12

)

(0.73

)

(0.68

)

(0.14

)

(0.82

)

Amortization of intangibles

0.19

—

0.19

—

0.19

Change in fair value of contingent consideration

—

0.01

—

0.01

Acquisition, restructuring and other items, net (3)

0.31

—

0.31

0.32

0.01

0.33

Tax effect of non-GAAP items (4)

0.03

0.06

0.04

0.03

0.07

Adjusted diluted loss per share

(0.08

)

(0.09

)

(0.17

)

(0.12

)

(0.10

)

(0.22

)

Adjusted diluted sharecount (5)

41,467

40,809

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

2025, respectively .

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain

litigation, and other items.

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax

assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.

(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands)

Reconciliation of Net Loss and non-GAAP Pro Forma Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA:

Nine Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Feb 28, 2026

Feb 28, 2025

(unaudited)

Net loss

(25,337

)

(5,002

)

(30,339

)

(27,943

)

(5,628

)

(33,571

)

Income tax expense

—

Interest expense (income), net

194

—

194

(975

)

—

(975

)

Depreciation and amortization

17,358

—

17,358

19,967

—

19,967

Change in fair value of contingent consideration

—

272

—

272

Stock based compensation

10,045

—

10,045

8,131

—

8,131

Acquisition, restructuring and other items, net (3)

12,578

—

12,578

10,239

161

10,400

Adjusted EBITDA

14,910

(5,002

)

9,908

9,712

(5,467

)

4,245

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

2025, respectively .

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain

litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL

(in thousands)

Three Months Ended

Nine Months Ended

Feb 28, 2026

Feb 28, 2025

Feb 28, 2026

Feb 28, 2025

(unaudited)

Legal (1)

146

—

1,831

406

Mergers and acquisitions

—

737

Plant closure (2)

5,195

3,130

9,911

11,820

Transition service agreement (3)

(555

)

(463

)

(1,523

)

(1,424

)

CEO retirement and transition(4)

870

—

870

—

Other

866

619

1,826

1,926

Total

6,522

3,286

12,915

13,465

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(3) Transition services agreements that were entered into with Merit and Spectrum.

(4) CEO retirement and transition expenses related to the CEO search and retention agreements with the Company's executive leadership team.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

Three Months Ended

Pro Forma

Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Feb 28, 2026

Feb 28, 2025

% Growth

(unaudited)

Net Sales

Med Tech

37,282

—

37,282

31,341

—

31,341

19.0

Med Device

41,141

)

41,139

40,663

40,672

1.2

1.1

78,423

)

78,421

72,004

72,013

8.9

Net Sales

United States

67,278

)

67,276

61,340

61,344

9.7

International

11,145

—

11,145

10,664

10,669

4.5

78,423

)

78,421

72,004

72,013

8.9

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

GROSS MARGIN BY PRODUCT CATEGORY

(in thousands)

Three Months Ended

Pro Forma

Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Feb 28, 2026

Feb 28, 2025

% Change

(unaudited)

Med Tech

23,292

—

23,292

19,588

—

19,588

18.9

Gross margin % of sales

62.5

Med Device

18,187

)

18,185

19,269

19,272

(5.6

Gross margin % of sales

44.2

47.4

Total

41,479

)

41,477

38,857

38,860

6.7

Gross margin % of sales

52.9

54.0

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

Nine Months Ended

Pro Forma

Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Feb 28, 2026

Feb 28, 2025

% Growth

(unaudited)

Net Sales

Med Tech

108,196

—

108,196

90,863

—

90,863

19.1

Med Device

125,371

)

125,369

121,477

188

121,665

3.2

3.0

233,567

)

233,565

212,340

188

212,528

10.0

9.9

Net Sales

United States

201,328

)

201,326

183,499

183,513

9.7

International

32,239

—

32,239

28,841

174

29,015

11.8

11.1

233,567

)

233,565

212,340

188

212,528

10.0

9.9

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

GROSS MARGIN BY PRODUCT CATEGORY

(in thousands)

Nine Months Ended

Pro Forma

Adjustments (2)

Pro Forma

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Feb 28, 2026

Feb 28, 2025

% Change

(unaudited)

Med Tech

68,500

—

68,500

57,398

—

57,398

19.3

Gross margin % of sales

63.3

63.2

Med Device

59,619

)

59,617

58,089

58,122

2.6

Gross margin % of sales

47.6

47.8

Total

128,119

)

128,117

115,487

115,520

10.9

Gross margin % of sales

54.9

54.4

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

Feb 28, 2026

May 31, 2025

(unaudited)

(audited)

Assets

Current assets:

Cash

37,810

55,893

Accounts receivable, net

45,552

42,890

Inventories

58,578

62,006

Prepaid expenses and other

13,612

7,535

Total current assets

155,552

168,324

Property, plant and equipment, net

29,142

32,300

Other assets

10,498

10,404

Intangible assets, net

65,486

69,116

Total assets

260,678

280,144

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

29,105

33,291

Accrued liabilities

32,303

35,518

Other current liabilities

4,658

7,388

Total current liabilities

66,066

76,197

Deferred income taxes

4,554

4,073

Other long-term liabilities

16,701

16,904

Total liabilities

87,321

97,174

Stockholders' equity

173,357

182,970

Total Liabilities and Stockholders' Equity

260,678

280,144

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended

Nine Months Ended

Feb 28, 2026

Feb 28, 2025

Feb 28, 2026

Feb 28, 2025

(unaudited)

Cash flows from operating activities:

Net loss

(8,084

)

(4,407

)

(25,337

)

(27,943

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

5,591

6,319

17,358

19,967

Non-cash lease expense

350

503

1,200

1,496

Non-cash interest expense

—

217

—

Stock based compensation

2,684

2,398

10,045

8,131

Change in fair value of contingent consideration

—

272

Deferred income taxes

(207

)

(795

)

Change in accounts receivable allowances

317

142

190

530

Fixed and intangible asset disposals

318

Other

315

817

149

Changes in operating assets and liabilities:

Accounts receivable

(1,418

)

(474

)

(2,847

)

(424

)

Inventories

7,057

2,810

3,584

(2,493

)

Prepaid expenses and other

(4,077

)

(9,387

)

(6,372

)

(9,459

)

Accounts payable, accrued and other liabilities

(6,012

)

(10,964

)

(13,529

)

(18,467

)

Net cash used in operating activities

(3,110

)

(13,159

)

(14,363

)

(28,939

)

Cash flows from investing activities:

Additions to property, plant and equipment

(1,015

)

(1,798

)

(2,168

)

(3,687

)

Additions to placement and evaluation units

(492

)

(1,391

)

(2,511

)

(3,868

)

Net cash used in investing activities

(1,507

)

(3,189

)

(4,679

)

(7,555

)

Cash flows from financing activities:

Proceeds from financing arrangement

—

6,310

—

6,310

Principal payments on finance arrangements

(95

)

(58

)

(278

)

(58

)

Repurchase of common stock

—

(1,670

)

Proceeds from exercise of stock options and employee stock purchase plan

716

895

950

933

Net cash provided by financing activities

621

7,147

672

5,515

Effect of exchange rate changes on cash

168

(128

)

287

(317

)

Decrease in cash

(3,828

)

(9,329

)

(18,083

)

(31,296

)

Cash at beginning of period

41,638

54,089

55,893

76,056

Cash at end of period

37,810

44,760

37,810

44,760

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: ef20069681_ex99-2.htm · Sequence: 3

Exhibit 99.2

Third Quarter FY 2026Earnings Results April 2, 2026

Forward looking statements 2 Notice Regarding Forward-Looking Statements This

presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows,

business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as

“expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are

not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the

actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by

competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially

greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation,

tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators,

the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market

conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or

approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025.

AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. Notice Regarding Non-GAAP Financial Measures Management uses non-GAAP measures to establish operational goals and

believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to,

financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation);

adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing

AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review

AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on

AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

3 Q3 FY 2026 Key Takeaways Continued commercial and operational execution drives

AngioDynamics’ accelerated and profitable growth. Continued Commercial Execution – Q3 FY 2026 Total +8.9% YoY Revenue Growth* Med Tech +19.0% Med Device +1.1% Auryon +17.9% Med Tech YoY Revenue Growth* Mech

Thrombectomy +17.9% NanoKnife Probes +20.0% Focus on Profitability Balance Sheet Strength Ended quarter with $37.8M in Cash Zero debt with flexibility of revolving line of credit Used ~$3.0M of cash in the quarter, slightly better

than previously guided Pro forma Adjusted EBITDA** of $1.8M, an improvement of $0.5M from Q3 FY 2025 Continued Execution Net sales of $78.4M, +8.9% YoY growth Med Tech segment sales of $37.3M, +19.0% YoY growth Med Device segment sales

of $41.1M, +1.1% YoY growth *All growth rates are pro forma ** Pro forma Adjusted EBITDA excludes the $5.0 million milestone payment received from Spectrum Vascular in Q3 of FY 2026 and the $5.5 million milestone payment received from

Spectrum Vascular in Q3 of FY 2025

4 Demonstrated Med Tech Growth Execution 4 Med Tech ~22% of Total Med Tech ~46% of

Total +15% - 17% *Guidance issued in conjunction with fiscal Q3 2026 earnings call on Apr 2, 2026 Med Tech 5yr CAGR: +25%

5 Q3 FY 2026 Financial Snapshot +1.1% Pro Forma Growth +19.0% Pro Forma

Growth Segment Revenue Contribution Segment Gross Margin 44.2% 62.5% Med Device Med Tech

6 Med Tech - Auryon Combination of Auryon’s best-in-class technology and our

commercial strategy have positioned Auryon as a consistently high-growth platform being supported by superior outcomes and ongoing investment to expand applicability Period Sales YoY Growth Q3 FY 2026 $16.3M 17.9% Continued share

capture through commercial execution Ongoing penetration into hospital setting provides higher ASPs and improving margins AMBITION BTK RCT and Registry ongoing

7 Med Tech – Thrombus Management Combination of AlphaVac and AngioVac represent a

strong, highly competitive mechanical thrombectomy portfolio which continues to take market share driven by expanded joint commercial strategy AlphaVac Second quarter of 40%+ YoY growth driven by growth in PE Sequential revenue increased

by roughly $850,000, a ~24% increase First patients enrolled in APEX-Return IDE study in March 2026 AngioVac FDA IDE approval obtained for PAVE clinical study in right-sided infective endocarditis (RSIE) Q3 FY 2026 Sales YoY

Growth AlphaVac $4.4M 47.4% AngioVac $7.2M 5.0% Total Mech Thromb. $11.5M 17.9% Unifuse $1.8M 27.5% Total Thrombus Mgmt. $13.3M 19.1%

8 Med Tech - NanoKnife Adoption has continued to accelerate within Prostate as this

novel therapy gains traction following receipt of FDA clearance in Dec 2024 Continued demand for NanoKnife for prostate driving increased utilization Prostate Tissue CPT Category 1 Code, effective Jan. 1, 2026. Streamlines reimbursement for

healthcare providers performing irreversible electroporation (IRE) ablation procedures Q3 FY 2026 Sales YoY Growth Disposables $5.9M 20.0% Capital $1.7M 24.9% Total $7.6M 21.0%

9 Compelling FY 2026 Financial Outlooksupported by balance sheet strength *Guidance

was issued in conjunction with fiscal Q3 FY 2026 earnings call on April 2, 2026 +15 - 17% Med Tech Metric Action Current Guidance Prior Guidance Net Sales Increased $313.5 - $315.5M $312 - $314M Med Tech Net Sales

Growth Increased +15% - 17% +14 – 16% Med Device Net Sales Growth Increased Approx. 1% +0 – 1% Gross Margin Unchanged 53.5 – 55.5% 53.5 – 55.5% Adjusted EBITDA Increased +$10.0 - $12.0M +$8.0 - $10.0M Adjusted

EPS Increased ($0.30) – ($0.23) ($0.33) – ($0.23) Approx. 1% Med Device FY 2026 Financial Guidance* FY 2026 Cash Guidance: Proactively increasing inventory may result in additional cash use in Q4, bringing full-year operating cash to

slightly negative, down from prior positive guidance. $37.8M in Cash at Feb 28, 2026 Zero debt on balance sheet with flexibility from revolving line of credit

10 Appendix

11 Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income

Statements (in thousand, except per share data)

12 Reconciliation of Net Loss to Non-GAAP Adjusted Net Income (Loss) and EPS and Pro

Forma Adjusted Net Loss and EPS (in thousands, except per share data) Reconciliation of Net Loss and non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA (in thousands)

13 Reconciliation of Net Loss to Non-GAAP Adjusted Net Loss and EPS and Pro Forma

Adjusted Net Loss and EPS (in thousands, except per share data) Reconciliation of Net Loss and Non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA (in thousands)

14 Detail of “Acquisition, Restructuring and Other Items, net” (in thousands)

15 Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by

Product Category (in thousands)

GRAPHIC

Filename: ef20069681_ex99-2slide1.jpg · Sequence: 7

Binary file (82791 bytes)

Download ef20069681_ex99-2slide1.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide2.jpg · Sequence: 8

Binary file (282049 bytes)

Download ef20069681_ex99-2slide2.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide3.jpg · Sequence: 9

Binary file (168195 bytes)

Download ef20069681_ex99-2slide3.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide4.jpg · Sequence: 10

Binary file (109906 bytes)

Download ef20069681_ex99-2slide4.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide5.jpg · Sequence: 11

Binary file (102292 bytes)

Download ef20069681_ex99-2slide5.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide6.jpg · Sequence: 12

Binary file (129862 bytes)

Download ef20069681_ex99-2slide6.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide7.jpg · Sequence: 13

Binary file (154852 bytes)

Download ef20069681_ex99-2slide7.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide8.jpg · Sequence: 14

Binary file (142637 bytes)

Download ef20069681_ex99-2slide8.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide9.jpg · Sequence: 15

Binary file (186978 bytes)

Download ef20069681_ex99-2slide9.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide10.jpg · Sequence: 16

Binary file (27392 bytes)

Download ef20069681_ex99-2slide10.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide11.jpg · Sequence: 17

Binary file (184830 bytes)

Download ef20069681_ex99-2slide11.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide12.jpg · Sequence: 18

Binary file (201612 bytes)

Download ef20069681_ex99-2slide12.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide13.jpg · Sequence: 19

Binary file (211740 bytes)

Download ef20069681_ex99-2slide13.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide14.jpg · Sequence: 20

Binary file (85421 bytes)

Download ef20069681_ex99-2slide14.jpg

GRAPHIC

Filename: ef20069681_ex99-2slide15.jpg · Sequence: 21

Binary file (180114 bytes)

Download ef20069681_ex99-2slide15.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 23

v3.26.1

Document and Entity Information

Apr. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 02, 2026

Entity File Number

000-50761

Entity Registrant Name

AngioDynamics, Inc.

Entity Central Index Key

0001275187

Entity Incorporation, State or Country Code

Entity Tax Identification Number

11-3146460

Entity Address, Address Line One

14 Plaza Drive

Entity Address, City or Town

Latham

Entity Address, State or Province

Entity Address, Postal Zip Code

12110

City Area Code

518

Local Phone Number

795-1400

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

ANGO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration